Cargando…

Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism

Fulvestrant (Faslodex™) is a pure antiestrogen that is effective in treating estrogen receptor-(ER) positive breast cancer tumors that are resistant to selective estrogen receptor modulators such as tamoxifen. Clinical trials investigating the utility of adding fulvestrant to other therapeutics have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edavana, Vineetha K, Penney, Rosalind B, Yao-Borengasser, Aiwei, Williams, Suzanne, Rogers, Lora, Dhakal, Ishwori B, Kadlubar, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841332/ https://www.ncbi.nlm.nih.gov/pubmed/24298433 http://dx.doi.org/10.1186/2193-1801-2-620

Ejemplares similares

Sulfotransferase 1A1 (SULT1A1) gene expression is regulated by members of the NFI transcription factors in human breast cancer cells
por: Yao-Borengasser, Aiwei, et al.
Publicado: (2014)

CYP19A1 single nucleotide polymorphism associations with CYP19A1, NFκB1, and IL6 gene expression in human normal colon and normal liver samples
por: Penney, Rosalind B, et al.
Publicado: (2014)

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1
por: Edavana, Vineetha Koroth, et al.
Publicado: (2011)

Lack of correlation between in silico projection of function and quantitative real-time PCR-determined gene expression levels in colon tissue
por: Penney, Rosalind B, et al.
Publicado: (2013)

Genotypic and Allelic Variability in CYP19A1 among Populations of African and European Ancestry
por: Starlard-Davenport, Athena, et al.
Publicado: (2015)

2-amino-1-methyl-6-phenylimidazo(4,5-b) pyridine (PhIP) induces gene expression changes in JAK/STAT and MAPK pathways related to inflammation, diabetes and cancer
por: Rogers, Lora J., et al.
Publicado: (2016)

Adipocyte hypoxia promotes epithelial-mesenchymal transition-related gene expression and estrogen receptor-negative phenotype in breast cancer cells
por: YAO-BORENGASSER, AIWEI, et al.
Publicado: (2015)

Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects
por: Yu, Xinfeng, et al.
Publicado: (2013)

Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells
por: Yu, Xinfeng, et al.
Publicado: (2012)

Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer
por: O’Leary, Ben, et al.
Publicado: (2020)

Modifications of hemoglobin and myoglobin by Maillard reaction products (MRPs)
por: Ioannou, Aristos, et al.
Publicado: (2017)

Plasmodium falciparum Multidrug Resistance Proteins (pfMRPs)
por: Gil, José Pedro, et al.
Publicado: (2021)

The value of RPS15 and MRPS27 in ischemic stroke
por: Zhao, Man, et al.
Publicado: (2023)

Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients
por: Wang, Ling-Zhi, et al.
Publicado: (2013)

Investigation of the role of multidrug resistance proteins (MRPs) in vascular homeostasis
por: Allen, Robert M H, et al.
Publicado: (2015)

MRPS25 mutations impair mitochondrial translation and cause encephalomyopathy
por: Bugiardini, Enrico, et al.
Publicado: (2019)

Correction: Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients
por: Wang, Ling-Zhi, et al.
Publicado: (2014)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
por: Cameron, D A, et al.
Publicado: (2008)

Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells
por: Traboulsi, Tatiana, et al.
Publicado: (2018)

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
por: Elias, Anthony D., et al.
Publicado: (2023)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

Genetic variants in the MRPS30 region and postmenopausal breast cancer risk
por: Huang, Ying, et al.
Publicado: (2011)

Genetic variants in the MRPS30 region and postmenopausal breast cancer risk
por: Huang, Ying, et al.
Publicado: (2012)

Mutation in MRPS34 Compromises Protein Synthesis and Causes Mitochondrial Dysfunction
por: Richman, Tara R., et al.
Publicado: (2015)

Day of surgery cancellation rate after preoperative telephone nurse screening or comprehensive optimization visit
por: Olson, Ronald P., et al.
Publicado: (2015)

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis
por: Xu, Tong, et al.
Publicado: (2022)

Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells
por: Hancock, G. R., et al.
Publicado: (2022)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
por: Mishra, Ameet K., et al.
Publicado: (2016)

Down-regulation of MRPS23 inhibits rat breast cancer proliferation and metastasis
por: Gao, Yan, et al.
Publicado: (2017)

Phenotype of Mrps5-Associated Phylogenetic Polymorphisms Is Intimately Linked to Mitoribosomal Misreading
por: Juskeviciene, Reda, et al.
Publicado: (2022)

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
por: Spoerke, Jill M., et al.
Publicado: (2016)

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017)

Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients
por: Liu, Jingyu, et al.
Publicado: (2019)

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
por: Smyth, Lillian M., et al.
Publicado: (2021)

ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
por: Chen, Jessica W., et al.
Publicado: (2023)

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents
por: Wang, Guangdi
Publicado: (2020)

Stem cell gene expression in MRPS18-2-immortalized rat embryonic fibroblasts
por: Yenamandra, S P, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_876hh1eg0m17037u3s3r7tl1qe